Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 5/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.42 |
| ▸ | PSD | A5PKW4 | 2/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.38 |
| ▸ | UCHL5 | Q9Y5K5 | 1/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | TEK | Q02763 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15182346 | 0.89 | ALDH1A1 (0.36) | AURKAHDAC3HDAC1HDAC6HDAC2 | |
| SCHEMBL3597235 | 0.82 | MEN1 (0.40) | AURKAKDRTEK | |
| SCHEMBL3596812 | 0.82 | SLC5A2 (0.32) | — | |
| SCHEMBL3596813 | 0.82 | SLC5A2 (0.32) | — | |
| SCHEMBL3583746 | 0.81 | MEN1 (0.37) | AURKAKDRTEK | |
| SCHEMBL3580710 | 0.81 | MAOA (0.31) | — | |
| SCHEMBL3583250 | 0.80 | MEN1 (0.40) | AURKAKDRTEK | |
| SCHEMBL15182173 | 0.77 | CCR1 (0.38) | — | |
| SCHEMBL3598373 | 0.77 | CNR1 (0.39) | CNR1 | |
| SCHEMBL3598375 | 0.77 | CNR1 (0.39) | CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130210769-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2013-08-15 | — | — | US | claimed |
| US-20100234365-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2010-09-16 | — | — | US | claimed |
| EP-2121598-A2 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2009-11-25 | — | — | EP | claimed |
| WO-2008076754-A2 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2008-06-26 | — | — | WO | claimed |
| US-20130210769-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2013-08-15 | — | — | US | disclosed |
| US-20130210769-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2013-08-15 | — | — | US | disclosed |
| US-8431607-B2 | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2013-04-30 | — | — | US | disclosed |
| US-8431607-B2 | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2013-04-30 | — | — | US | disclosed |
| US-20100234365-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2010-09-16 | — | — | US | disclosed |
| US-20100234365-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2010-09-16 | — | — | US | disclosed |
| EP-2121598-A2 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008076754-A2 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008076754-A2 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210769-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | CNR1, CNR2, FAAH | AURKA 3469/4885AURKB 3415/4885PSD 1562/4885 |
| US-20100234365-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | CNR1, CNR2, FAAH | AURKA 3469/4885AURKB 3415/4885PSD 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.